2026年11月4日星期三
M
Chroniques universelles
Flash info mondial
US experts warm to Japanese nuclear subs as check on China in Asian waters— 日经 Nikkei AsiaDRAM prices double in 2026 as AI focus squeezes PC makers— 日经 Nikkei AsiaJapan weighs standards for self-driving cars without steering wheels— 日经 Nikkei AsiaMitsubishi to sell part of stake in Canada LNG project to Blackstone funds— 日经 Nikkei AsiaJapan's SBI to invest in US digital bank Erebor, eyeing blockchain settlements— 日经 Nikkei AsiaAnthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaUS midterms live: Flooding forces polling sites to relocate— 日经 Nikkei AsiaUS experts warm to Japanese nuclear subs as check on China in Asian waters— 日经 Nikkei AsiaDRAM prices double in 2026 as AI focus squeezes PC makers— 日经 Nikkei AsiaJapan weighs standards for self-driving cars without steering wheels— 日经 Nikkei AsiaMitsubishi to sell part of stake in Canada LNG project to Blackstone funds— 日经 Nikkei AsiaJapan's SBI to invest in US digital bank Erebor, eyeing blockchain settlements— 日经 Nikkei AsiaAnthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaUS midterms live: Flooding forces polling sites to relocate— 日经 Nikkei Asia

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial

Source 柳叶刀 Lancetil y a 10 jours
Résumé du contenu

Mitapivat, an oral pyruvate kinase activator, with a novel mechanism that ameliorates haemolytic anaemia, has the potential to be an effective and convenient d…

Ce site ne fournit qu'un index de titres et de résumés ; le contenu complet et les droits d'auteur appartiennent à l'éditeur d'origine. Veuillez cliquer sur le lien original pour lire.

Aller à l'article original
Chaîne d'appartenance
Santé
Région d'appartenance
Royaume-Uni
Langue de l'original
English
Numéro d'entrée
health-94d31632

Comments 0 comments

No comments yet. Be the first.

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial · Chroniques universelles